Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Edetate Disodium Clear all
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

NCT00001575
View directory record Official record
Conditions
Hodgkin's Disease, Lymphoma, Non-Hodgkin
Interventions
Y-90 Humanized Anti-Tac, Calcium-DTPA
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

NCT04078191
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Beverly Hills, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

NCT00874887
View directory record Official record
Conditions
Anti-biotic Resistance
Interventions
moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Chelation Therapy 2

NCT02733185
View directory record Official record
Conditions
Diabetes, Myocardial Infarction
Interventions
disodium EDTA, Oral Multi Vitamins/Minerals (OMVM), Placebo disodium EDTA, Placebo Oral Multi Vitamins/Minerals (OMVM)
Drug · Dietary Supplement
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

ASIS for Enbrel in Plaque Psoriasis

NCT02112097
View directory record Official record
Conditions
Plaque Psoriasis.
Interventions
Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

NCT02683421
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 11, 2026, 5:14 PM EDT
Completed No phase listed Observational

Perioperative Tissue Penetration of Antimicrobials in Infants

NCT04299867
View directory record Official record
Conditions
Bowel Dysfunction
Interventions
Bowel Surgery with Metronidazole
Procedure
Lead sponsor
Duke University
Other
Eligibility
0 Years to 2 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

NCT02871882
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obese, Overweight
Interventions
Gastric Emptying test, Mixed Oral Glucose Tolerance test, Conjugated bile acids sodium, Placebo
Radiation · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Early Phase 1 Interventional

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

NCT03424746
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease
Interventions
disodium EDTA
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

NCT02509598
View directory record Official record
Conditions
Rhabdomyosarcoma, Melanoma
Interventions
Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
Drug · Procedure
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

NCT03938636
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Mapping Draining Lymph Nodes in CNS Malignancies

NCT04096716
View directory record Official record
Conditions
Central Nervous System Neoplasms, Central Nervous System Tumor
Interventions
Tc-99m tilmanocept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

NCT03694756
View directory record Official record
Conditions
Breast Cancer
Interventions
TMEM-MRI, FNA
Device · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

NCT04947137
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tc99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Miami Lakes, Florida • Palmetto Bay, Florida • Kettering, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Results available

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

NCT03157167
View directory record Official record
Conditions
Kaposi Sarcoma, HIV Infections
Interventions
Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 11, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

NCT05811923
View directory record Official record
Conditions
Metabolic Syndrome, Caffeine
Interventions
Venous Blood Collection, Resting Metabolic Rate Determination, Mood State, Visual Analog Scales
Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 11, 2026, 5:14 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Cervical Dystonia

NCT02074293
View directory record Official record
Conditions
Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 11, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

NCT05246280
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TC99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Beverly Hills, California • San Francisco, California • Avon Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 11, 2026, 5:14 PM EDT